Jefferies Reiterates Buy on NuVasive (NUVA) Following 3Q Report
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Jefferies reiterated a Buy rating and $72.00 price target on NuVasive (NASDAQ: NUVA) following the company's 3Q earnings report. For the year, the company is now guiding to $952mn in sales (down from $962mn). Components of this include the US capital stocking issue of $3.5mn and the negative impact to Japanese sales from the dilator reclassification. Despite the minor hiccup and the first case of guidance being lowered in recent memory, the NUVA story is largely intact.
Analyst Raj Denhoy commented, "3Q sales came in $3mn shy of guidance ($240mn v. ~$243mn); EPS was in line at $0.40. The top-line miss was $3.5mn in US capital and stock orders that did not materializing as expected. For FY16, revenue guidance was lowered by $10mn to reflect this $3.5mn plus $6mn in previously expected XLIF sales from the delay of a dilator reclassification in Japan. The issues in 3Q are transitory and the share gain and profit improvement story at NUVA is firmly intact."
Shares of NuVasive closed at $65.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Skyworks Solutions (SWKS) PT Raised to $105 at Oppenheimer Following 1Q Report
- Drexel Hamilton Reiterates Buy on IBM (IBM) Following 4Q Report
- Bassett Furniture (BSET) PT Raised to $28 at Stifel Following 4Q EPS Beat
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View
Related EntitiesJefferies & Co, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!